E
Sell
9/25/2024Downgrade
Intensity Therapeutics, Inc. (INTS) was downgraded to E+ from D- on 9/25/2024 due to a decline in the volatility index, solvency index and valuation index. The quick ratio declined from 4.17 to 1.97.
D
Sell
5/28/2024Upgraded
Intensity Therapeutics, Inc. (INTS) was upgraded to D- from E+ on 5/28/2024 due to an increase in the volatility index.
E
Sell
4/17/2024Downgrade
Intensity Therapeutics, Inc. (INTS) was downgraded to E+ from D- on 4/17/2024 due to a noticeable decline in the growth index, valuation index and volatility index. Earnings per share declined from -$0.1705 to -$0.2304, and EBIT declined 34.62% from -$2.49M to -$3.35M.
D
Sell
3/1/2024Upgraded
Intensity Therapeutics, Inc. (INTS) was upgraded to D- from E on 3/1/2024 due to a noticeable increase in the volatility index, total return index and growth index.
E
Sell
12/1/2023Upgraded
Intensity Therapeutics, Inc. (INTS) was upgraded to E from E- on 12/1/2023 due to an increase in the solvency index, valuation index and growth index. The quick ratio increased from 5.88 to 21.64, and earnings per share increased from -$1.3843 to -$0.1705.
E
Sell
9/25/2023None
Intensity Therapeutics, Inc. (INTS) was downgraded to E- from U on 09/25/2023.
